top of page
Accelerating antiviral drug discovery: lessons from COVID-19

We analyze the force multipliers behind rapid COVID drug discovery efforts. Our work draws from expertise in multiple leading pharmaceutical companies with successful antivirals in the clinic as well as public sector efforts. We suggest that the key bottleneck is the lack of quality chemical probes around understudied viral targets, and building an arsenal of probes covering viruses of pandemic concern is a worthwhile and tractable challenge.

Why we are developing a patent-free Covid antiviral therapy

We discuss the policy argument behind open science drug discovery for pandemic preparedness. 

Get (1).jpeg
Discovery of SARS-CoV-2 main protease inhibitors using a synthesis-directed de novo design model

We show how machine learning expedite the discovery of SARS-CoV-2 main protease inhibitors, validated with biochemical and antiviral assays. The key to our approach is the use of machine learning for de novo design, coupled with synthesis route prediction. 

Screen Shot 2021-03-24 at 16.28.24.png
Crowdsourcing drug discovery for pandemics

We launch the COVID Moonshot initiative, an open-science initiative that aims to discovery oral antiviral against SARS-CoV-2 targeting the main protease.

bottom of page